Viridian Therapeutics, Inc.

VRDN · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$270-$238-$130-$79
Dep. & Amort.$1$1$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$42$67$20$14
Change in WC$10-$9$16$2
Other Non-Cash-$15-$5$0$9
Operating Cash Flow-$232-$184-$94-$55
Investing Activities
PP&E Inv.-$1-$1-$1-$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$695-$408-$223-$188
Inv. Sales/Matur.$467$315$109$114
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$229-$94-$115-$74
Financing Activities
Debt Repay.$0$15$5$0
Stock Issued$454$125$292$114
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$4$86$25$11
Financing Cash Flow$458$226$322$125
Forex Effect$0$0$0$0
Net Chg. in Cash-$3-$53$113-$4
Supplemental Information
Beg. Cash$103$156$42$46
End Cash$100$103$156$42
Free Cash Flow-$233-$185-$95-$55
Viridian Therapeutics, Inc. (VRDN) Financial Statements & Key Stats | AlphaPilot